Geoffrey Shouse, D.O., Ph.D.
— Patient”
Geoffrey Shouse, D.O., Ph.D.'s fascination with molecular biology led him to hematology and oncology as a career. He earned a Ph.D. in cell, molecular and developmental biology at the University of California Riverside, and went on to study medicine at Western University of Health Sciences in Pomona, California. He continued his residency and fellowship training at Loma Linda University Medical Center, with additional fellowship training at City of Hope in stem cell transplant and cellular therapy.
Dr. Shouse focuses his research on eliminating the barriers of lymphoma cure. He is the primary investigator on numerous clinical trials including utilizing cutting edge treatments to more effectively treat lymphoma. These include cell therapies, molecular targeted therapies and immunotherapy. In addition, he leads studies designed to improve outcomes in older adults facing the sometimes daunting toxicities of lymphoma therapy. Finally, he designs and implements clinical trials focused on enhanced access and recruitment of underrepresented minorities.
He cares deeply about his patients and has become an essential member of City of Hope's team.
Duarte - Main Campus
Duarte, CA 91010
2007-2012, Ph.D., Osteopathic Medicine, Western University of Health Sciences, Pomona, CA
2003-2009, Ph.D., Cell, Molecular, and Developmental Biology, University of California Riverside, Riverside, CA
1998-2002, B.S., Biology, University of California Riverside, Riverside, CA
2019, Fellowship in Bone Marrow Transplantation, City of Hope, Duarte, CA
2015-2018, Fellowship in Hematology and Medical Oncology, Loma Linda University Medical Center, Loma Linda, CA
2006-2012, Postdoctoral Fellow, Cell, Molecular and Developmental
Biology, Department of Biochemistry, University of California Riverside, Riverside, CA
2012-2015, Internal Medicine, Loma Linda University Medical Center, Loma Linda, CA
2020-present, Assistant Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
2018, Assistant Professor of Medicine, Division of Hematology and Oncology, Loma Linda University Medical Center, Loma Linda, CA
2021, Department of Hematology Pilot Project Grant, City of Hope, Department of Hematology & Hematopoietic Cell Transplantation, Duarte, CA
2021, CARinG Pilot Grant Award, Cancer and Aging Research Group, Duarte, CA
2021, Clinical Research Training Institute, American Society of Hematology, La Jolla, CA
2018, First Place Resident and Fellows Poster, Loma Linda University Medical Center, Loma Linda, CA
2015, Evidence-Based Medicine Award, Internal Medicine Residency, Loma Linda University Medical Center, Loma Linda, CA
2015, Research Award, Internal Medicine Residency, Loma Linda University Medical Center, Loma Linda, CA
2015, First Place Resident and Fellows Poster, Annual Postgraduate Conference, Loma Linda University Medical Center, Loma Linda, CA
2014, Abstract Achievement Award, ASH Annual Meeting, American Society of Hematology
2013-2015, Research Scholar, Internal Medicine Residency, Loma Linda University Medical Center, Loma Linda, CA
2013, Third Place Resident Poster Presentation, ACP Regional Meeting, American College of Physicians
2013, Best Resident Poster Presentation, SGIM Regional Meeting, Society of General Internal Medicine
2011, STARS Research Award, STARS Symposium, Western University of Health Sciences, Pomona, CA
2007, Research Award, CMDB Research Symposium, University of California Riverside, Riverside, CA
2005, Outstanding Teaching Assistant, Graduate Program in CMDB, University of California Riverside, Riverside, CA
2003-2004, Graduate Division Fellowship, Graduate Program in CMDB, University of California Riverside, Riverside, CA
1998-2002, Dean's Honor List, Undergraduate Award, University of California Riverside, Riverside, CA
2019-present, American Society of Transplantation and Cellular Therapy
2017-present, American Society of Hematology
2015-present American Society of Clinical Oncology
2012-present, American College of Physicians
2012-present, Society of General Internal Medicine
2007-present, American Osteopathic Association
2007-present, American Medical Association
- Shouse, G. Update on bispecific monoclonal antibodies for blood cancers. Curr Opin Oncol. 2023 Sep 1;35(5):441-445..
- *Kambhampati, S, *Shouse, G, and Danolov AV. Thinking “outside the germinal center”: Re-educating T cells to combat follicular lymphoma. Blood Rev. 2023 May 8;101099. *Equal contribution
- Epperla N, Welkie RL, Torka P, Shouse G, et al. Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study. J Hematol Oncol. 2023 May 8;16(1):49.
- Shouse, G, Kaempf, A, …, and Danilov, A.V. A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B cell lymphoma. Blood Advances (2023) Feb 3; Online ahead of print.
- Epperla, N, Zhao, Q, Chowdhur, SM…, and Shouse, G. Postibrutinib relapse outcomes for patients with marginal zone lymphoma. Blood Adv. 2023 Jan 10;7(1):88-91.
- Epperla, N, Zhao, Q, …, Herrera, A, and Shouse, G. Predictive Factors and Outcomes for Ibrutinib in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study. J Hematol Oncol (2022) Jul 16;15(1):96.
- Shouse, G, Danilova, OV, and Danilov, AV. Current status of phosphoinotiside-3 kinase inhibitors in blood cancers. Curr Opin Oncol. 2022 Sep 1;34(5):540-545.
- Zurko, JC, Nizamuddin, I, Epperla, N…Shouse, G, and Karmali, R. Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL. Blood Adv 2022008240.
- Shouse, G, Danilov, A, Artz, A. CAR T-Cell Therapy in the Older Person: Indications and Risks. Current Oncology Reports. Curr Oncol Rep. 2022 Sep;24(9):1189-1199.
- Shouse, G and Herrera, A. Advances in Immunotherapy for Diffuse Large B Cell Lymphoma. BioDrugs. 2021. Sep;35(5):517-528.